Novartis's Glivec recommended for adjuvant treatment of GIST in EU
This article was originally published in Scrip
Executive Summary
Novartis's Glivec (imatinib) has been recommended for EU approval by the CHMP for the adjuvant treatment of patients at significant risk of relapse following surgical removal of Kit-positive gastrointestinal stromal tumours (GIST).